Balancing Near-Term Execution Risk With Long-Term EBITDA Upside: Why Evolent Remains a Buy Despite a Lowered Target

In a report released yesterday, Sean Dodge from BMO Capital maintained a Buy rating on Evolent Health, with a price target of $3.50.

Sean Dodge has given his Buy rating due to a combination of factors that balance near-term execution risk with attractive long-term earnings potential. He highlights that Evolent’s strong pace of new Performance Suite and risk-contract wins, including major deals with CVS/Aetna and Highmark, underpins the company’s 2026 revenue targets and provides solid top-line visibility despite known revenue headwinds from divestitures and client losses.

At the same time, Dodge acknowledges that the structure of these contracts creates an initial drag on EBITDA, pushing most profit contribution into the back half of 2026 and placing greater emphasis on consistent execution. Still, he views the company’s actions to reduce volatility, the improving value-based care backdrop, margin maturation, and AI-driven efficiencies as key drivers of a post‑2026 EBITDA growth profile exceeding 20%, which supports maintaining a Buy recommendation even after lowering the price target on peer multiple compression and tempered 2026 EBITDA expectations.

In another report released today, BTIG also maintained a Buy rating on the stock with a $8.00 price target.